Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Adds 148 New Drugs to Basic Insurance List

publication date: Aug 20, 2019

China has added 148 drugs to its list of medicines covered by basic medical insurance plans, the first update in two years. The additions were comprised of 47 western drugs and 101 TCM products, including medicines for cancers, rare diseases, chronic diseases and children’s diseases, as well as some basic drugs. Still unfinished is an additional list that includes expensive drugs of high clinical value, the new therapies for cancer and other medications. These drugs require price negotiations with drug pharmas over the China cost of the products, particularly for western biopharma companies. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China